Literature DB >> 11238298

Characteristics of an Albumin Cobalt Binding Test for assessment of acute coronary syndrome patients: a multicenter study.

R H Christenson1, S H Duh, W R Sanhai, A H Wu, V Holtman, P Painter, E Branham, F S Apple, M Murakami, D L Morris.   

Abstract

BACKGROUND: The ability of the N-terminal region of human albumin to bind cobalt is diminished by myocardial ischemia. The characteristics of an assay based on albumin cobalt binding were assessed in suspected acute coronary syndrome patients and in a control reference population. The ability of the Albumin Cobalt Binding (ACB) Test measurement at presentation to predict troponin-positive or -negative results 6-24 h later was also examined.
METHODS: We enrolled 256 acute coronary syndrome patients at four medical centers. Blood specimens were collected at presentation and then 6-24 h later. The dichotomous decision limit and performance characteristics of the ACB Test for predicting troponin-positive or -negative status 6 h-24 h later were determined using ROC curve analysis. Results for 32 patients could not be used because the time of onset of ischemia appeared to have been >3 h before presentation or was uncertain. The reference interval was determined by parametric analysis to estimate the upper 95th percentile of a reference population (n = 109) of ostensibly healthy individuals.
RESULTS: Increased cTnI was found in 35 of 224 patients. The ROC curve area for the ACB Test was 0.78 [95% confidence interval (CI), 0.70-0.86]. At the optimum decision point of 75 units/mL, the sensitivity and specificity of the ACB Test were 83% (95% CI, 66-93%) and 69% (95% CI, 62-76%). The negative predictive value was 96% (95% CI, 91-98%), and the positive predictive value was 33% (95% CI, 24-44%). The within-run CV of the ACB Test was 7.3%. Results for the reference population were normally distributed; the one-sided parametric 95th percentile was 80.2 units/mL.
CONCLUSIONS: This exploratory study suggests that the ACB Test has high negative predictive value and sensitivity in the presentation sample for predicting troponin-negative or -positive results 6-24 h later.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238298

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  40 in total

1.  Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome.

Authors:  Andrew Worster; P J Devereaux; Diane Heels-Ansdell; Gordon H Guyatt; John Opie; Farouk Mookadam; Stephen A Hill
Journal:  CMAJ       Date:  2005-06-21       Impact factor: 8.262

2.  Evaluation of effects of ischaemia on the albumin cobalt binding (ACB) assay in patients exposed to trauma.

Authors:  M Can; S Demirtas; O Polat; A Yildiz
Journal:  Emerg Med J       Date:  2006-07       Impact factor: 2.740

3.  Role of "Ischemia Modified Albumin" (IMA) in acute coronary syndromes.

Authors:  C Bhakthavatsala Reddy; Cijo Cyriac; Hrishikesh B Desle
Journal:  Indian Heart J       Date:  2014-12-22

4.  Glycogen Phosphorylase BB: A more Sensitive and Specific Marker than Other Cardiac Markers for Early Diagnosis of Acute Myocardial Infarction.

Authors:  Neelima Singh; Vedika Rathore; Roshan Kumar Mahat; Puneet Rastogi
Journal:  Indian J Clin Biochem       Date:  2017-08-03

5.  Prognostic value of combination of heart-type fatty acid-binding protein and ischemia-modified albumin in patients with acute coronary syndromes and normal troponin T values.

Authors:  Cui Liyan; Zhang Jie; Hu Xiaozhou
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

6.  Assay of ischemia-modified albumin and C-reactive protein for early diagnosis of acute coronary syndromes.

Authors:  Cui Liyan; Zhang Jie; Wu Yonghua; Hu Xiaozhou
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

7.  Effect of hemodialysis on traditional and innovative cardiac markers.

Authors:  Martina Montagnana; Giuseppe Lippi; Nicola Tessitore; Gian Luca Salvagno; Giovanni Targher; Matteo Gelati; Antonio Lupo; Gian Cesare Guidi
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

8.  Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease.

Authors:  Luiz Carlos Cichota; Rafael Noal Moresco; Marta Maria Medeiros Frescura Duarte; José Edson Paz da Silva
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

9.  The Role of Ischemia Modified Albumin as a Biomarker in Patients with Chronic Liver Disease.

Authors:  Prashanth Ashok Kumar; Kavitha Subramanian
Journal:  J Clin Diagn Res       Date:  2016-03-01

10.  Quick identification of acute chest pain patients study (QICS).

Authors:  Hendrik M Willemsen; Gonda de Jong; René A Tio; Wybe Nieuwland; Ido P Kema; Iwan C C van der Horst; Mattijs Oudkerk; Felix Zijlstra
Journal:  BMC Cardiovasc Disord       Date:  2009-06-15       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.